Rare Biomarkers Specimen Collection And Stabilization Market Size, Share & Trends Analysis Report By Biomarker, By End-use (Research, Diagnostics), By Region, And Segment Forecasts, 2023 - 2030

Report
209 Pages
September 2023
Region: Global
Grand View Research
ID: 5893289

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 84.18 billion by 2030, expanding at a CAGR of 12.2% over the forecast period. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.

Rare Biomarkers Specimen Collection And Stabilization Market Report Highlights

Currently, cfDNA and CTCs have collectively accounted for the major revenue share in 2022
Presence of commercially approved products for clinical-use is one of the high impact rendering drivers for these segments
Circulating RNA-based biomarkers are estimated to account for the lowest market penetration owing to the absence of commercial products for clinical practice
Furthermore, isolation of circulating RNAs poses challenges with regard to the purity and quality of samples. This has hampered the revenue growth of this segment to a considerable extent
The frequent purchase rate and wide availability of commercial products has led to the large revenue share of isolation kits and reagents under exosomes/extracellular vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA segments
Relatively less usage and purchase rate along with low product penetration of blood collection tubes in this space has slowed revenue growth in this segment
Presence of approved liquid biopsy tests coupled with an exponential increase in cancer-related research programs has contributed to the dominance of the oncology segment
North America led the market owing to the presence of key biotechnology and diagnostic laboratories in U.S.
Furthermore, defined regulatory structure for approval of novel assays has also contributed to the large share of this region
Some players operating in the rare biomarkers specimen collection and stabilization market are QIAGEN; Bio-Techne Corporation; Biocept, Inc.; GILUPI GmbH; and Norgen Biotek Corp
Key players are implementing various strategies to strengthen their product portfolios and offer diverse technologically advanced isolation products across various end-use settings.

This product will be delivered within 1-3 business days.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Biomarker
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Biomarker outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Rare Biomarkers Specimen Collection And Stabilization Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Rare Biomarkers Specimen Collection And Stabilization Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Rare Biomarkers Specimen Collection And Stabilization: Biomarker Estimates & Trend Analysis

4.1. Rare Biomarkers Specimen Collection And Stabilization Market: Key Takeaways
4.2. Rare Biomarkers Specimen Collection And Stabilization Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Circulating Cell Free DNA (ccfDNA)
4.3.1. Circulating cell free DNA (ccfDNA) market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4. Circulating Tumor Cells (CTCs)
4.4.1. Circulating tumor cells (CTCs) market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5. Exosomes/Extracellular Vesicles
4.5.1. Exosomes/Extracellular vesicles market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2. Product
4.5.2.1. Product market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.2. Isolation kits & reagents
4.5.2.2.1. Isolation kits & reagents market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.3. Blood collection tubes
4.5.2.3.1. Blood collection tubes market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.4. Systems
4.5.2.4.1. Systems market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3. Specimen type
4.5.3.1. Specimen type market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3.2. Serum/Plasma
4.5.3.2.1. Serum/Plasma market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3.3. Others
4.5.3.3.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4. Nucleic acid & other biomolecules
4.5.4.1. Nucleic acid & other biomolecules market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.2. RNA
4.5.4.2.1. RNA market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.3. DNA
4.5.4.3.1. DNA market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.4. Others
4.5.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5. Application
4.5.5.1. Application market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.2. NIPT
4.5.5.2.1. NIPT market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3. Oncology
4.5.5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.2. Research
4.5.5.3.2.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3. Diagnostics
4.5.5.3.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3.2. Screening
4.5.5.3.3.2.1. Screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3.3. Treatment monitoring
4.5.5.3.3.3.1. Treatment Monitoring market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.4. Transcriptomics
4.5.5.4.1. Transcriptomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.5. Pharmacogenomics
4.5.5.5.1. Pharmacogenomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.6. Transplant rejection
4.5.5.6.1. Transplant rejection market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.7. Population screening
4.5.5.7.1. Population screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.8. Cardiovascular diseases
4.5.5.8.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.9. Other applications
4.5.5.9.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6. Circulating Cell Free RNA (ccfRNA) / miRNA
4.6.1. Circulating cell free RNA (ccfRNA) / miRNAmarket estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2. Product
4.6.2.1. Product market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2.2. Isolation kits & reagents
4.6.2.2.1. Isolation kits & reagents market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2.3. Blood collection tubes
4.6.2.3.1. Blood collection tubes market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3. Application
4.6.3.1. Application market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.2. NIPT
4.6.3.2.1. NIPT market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3. Oncology
4.6.3.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3.2. Research
4.6.3.3.2.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3.3. Diagnostics
4.6.3.3.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.4. Transcriptomics
4.6.3.4.1. Transcriptomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.5. Pharmacogenomics
4.6.3.5.1. Pharmacogenomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.6. Transplant rejection
4.6.3.6.1. Transplant rejection market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.7. Population screening
4.6.3.7.1. Population screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.8. Cardiovascular diseases
4.6.3.8.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.9. Other applications
4.6.3.9.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Rare Biomarkers Specimen Collection And Stabilization: End Use Estimates & Trend Analysis

5.1. Rare Biomarkers Specimen Collection and Stabilization Market: Key Takeaways
5.2. Rare Biomarkers Specimen Collection and Stabilization Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Research
5.3.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
5.3.2. Research labs/CROs
5.3.2.1. Research labs/CROs market estimates and forecasts, 2018 to 2030 (USD Billion)
5.3.3. Academic institutes
5.3.3.1. Academic institutes market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4. Diagnostics
5.4.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.2. Laboratories
5.4.2.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.3. Hospitals
5.4.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.4. Prenatal clinics
5.4.4.1. Prenatal clinics market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Rare Biomarkers Specimen Collection And Stabilization Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Rare Biomarkers Specimen Collection And Stabilization Market by Region: Key Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. QIAGEN
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Charles River Laboratories
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. F. Hoffmann-La Roche Ltd
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Thermofischer Scientific Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Eurofins Scientific
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. PerkinElmer Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Bio-Rad Laboratories, Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Agilent Technologies, Inc
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Merck KGaA
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Siemens Healthcare GmbH
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 3 North America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 4 North America rare biomarkers specimen collection and stabilization market, by region, 2018 - 2030 (USD Billion)
Table 5 U.S. rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 6 U.S. rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 7 Canada rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 8 Canada rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 9 Europe rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 10 Europe rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 11 Europe rare biomarkers specimen collection and stabilization market, by region, 2018 - 2030 (USD Billion)
Table 12 UK rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 13 UK rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 14 Germany rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 15 Germany rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 16 France rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 17 France rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 18 Italy rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 19 Italy rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 20 Spain rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 21 Spain rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 22 Denmark rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 23 Denmark rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 24 Sweden rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 25 Sweden rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 26 Norway rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 27 Norway rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 28 Asia Pacific rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 29 Asia Pacific rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 30 Asia Pacific rare biomarkers specimen collection and stabilization market, by region, 2018 - 2030 (USD Billion)
Table 31 Japan rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 32 Japan rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 33 China rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 34 China rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 35 India rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 36 India rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 37 Thailand rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 38 Thailand rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 39 South Korea rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 40 South Korea rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 41 Latin America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 42 Latin America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 43 Latin America rare biomarkers specimen collection and stabilization market, by region, 2018 - 2030 (USD Billion)
Table 44 Brazil rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 45 Brazil rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 46 Mexico rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 47 Mexico rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 48 Argentina rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 49 Argentina rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 50 Middle East and Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 51 Middle East and Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 52 Middle East and Africa rare biomarkers specimen collection and stabilization market, by region, 2018 - 2030 (USD Billion)
Table 53 South Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 54 South Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 55 Saudi Arabia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 56 Saudi Arabia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 57 UAE rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 58 UAE rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)
Table 59 Kuwait rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Billion)
Table 60 Kuwait rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Rare biomarkers specimen collection and stabilization: Market outlook
Fig. 8 Rare biomarkers specimen collection and stabilization: Competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 Rare biomarkers specimen collection and stabilization market driver impact
Fig. 14 Rare biomarkers specimen collection and stabilization market restraint impact
Fig. 15 Rare biomarkers specimen collection and stabilization market strategic initiatives analysis
Fig. 16 Rare biomarkers specimen collection and stabilization market: Biomarker movement analysis
Fig. 17 Rare biomarkers specimen collection and stabilization market: Biomarker outlook and key takeaways
Fig. 18 Circulating cell free DNA (ccfDNA) market estimates and forecasts, 2018 - 2030
Fig. 19 Circulating tumor cells (CTCs) market estimates and forecasts, 2018 - 2030
Fig. 20 Exosomes/extracellular vesicles market estimates and forecasts, 2018 - 2030
Fig. 21 Circulating cell free RNA (ccfRNA) / miRNA market estimates and forecasts, 2018 - 2030
Fig. 22 Rare biomarkers specimen collection and stabilization market: End use movement analysis
Fig. 23 Rare biomarkers specimen collection and stabilization market: End use outlook and key takeaways
Fig. 24 Research market estimates and forecasts, 2018 - 2030
Fig. 25 Diagnostics market estimates and forecasts, 2018 - 2030
Fig. 26 Global rare biomarkers specimen collection and stabilization market: Regional movement analysis
Fig. 27 Global rare biomarkers specimen collection and stabilization market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030
Fig. 30 Canada market estimates and forecasts, 2018 - 2030
Fig. 31 Europe market estimates and forecasts, 2018 - 2030
Fig. 32 UK market estimates and forecasts, 2018 - 2030
Fig. 33 Germany market estimates and forecasts, 2018 - 2030
Fig. 34 France market estimates and forecasts, 2018 - 2030
Fig. 35 Italy market estimates and forecasts, 2018 - 2030
Fig. 36 Spain market estimates and forecasts, 2018 - 2030
Fig. 37 Denmark market estimates and forecasts, 2018 - 2030
Fig. 38 Sweden market estimates and forecasts, 2018 - 2030
Fig. 39 Norway market estimates and forecasts, 2018 - 2030
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 41 Japan market estimates and forecasts, 2018 - 2030
Fig. 42 China market estimates and forecasts, 2018 - 2030
Fig. 43 India market estimates and forecasts, 2018 - 2030
Fig. 44 Australia market estimates and forecasts, 2018 - 2030
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030
Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 52 South Africa market estimates and forecasts, 2018 - 2030
Fig. 53 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 54 UAE market estimates and forecasts, 2018 - 2030
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030

Companies Mentioned

QIAGEN
Charles River Laboratories
F. Hoffmann-La Roche Ltd
Thermofischer Scientific Inc.
Eurofins Scientific
PerkinElmer Inc.
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc
Merck KGaA
Siemens Healthcare GmbH

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	209
Published	September 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 33.9 Billion
Forecasted Market Value ( USD ) by 2030	$ 84.18 Billion
Compound Annual Growth Rate	12.2%
Regions Covered	Global
No. of Companies Mentioned	10

PURCHASE OPTIONS

Single User License PDF

1 - 5 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5736EUR$5,950USD£4,906GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6701EUR$6,950USD£5,731GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8629EUR$8,950USD£7,380GBP

Rare Biomarkers Specimen Collection And Stabilization Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Rare Biomarkers Specimen Collection & Stabilization Market by Product Type, Collection Type, Application, End Use - Forecast 2024-2030

Rare Biomarkers Specimen Collection and Stabilization - Global Strategic Business Report

Global Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Application (Clinical/Liquid Biopsy, Research), Specimen (Bone Marrow, Blood), Product, Technology, End-use, Region, and Segment Forecasts, 2024-2030

Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Surrogate Endpoints), By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030